Heart Failure (eBook)
302 Seiten
Wiley (Verlag)
978-0-470-02932-9 (ISBN)
This book describes the work of leading investigators studying the basic mechanisms of cardiac growth, function and dysfunction. There are also exciting contributions from researchers developing novel therapeutic strategies for cardiac disease. The unique feature is the discussions amongst the contributors, which always return to the same basic problem: how can new data from biological studies be used to design novel therapies for the treatment of cardiac dysfunction following myocardial infarction, hypertension and other disorders?
With its strong emphasis on translational research, this book will appeal to both scientists and clinicians interested in diminishing the impact of the current epidemic of cardiac diseases.
The Novartis Foundation is an international scientific and educational charity which promotes the study and general knowledge of science and in particular encourages international co-operation in scientific research.
Heart failure is the main cause of death and disability in the industrialized world. There is a major need for novel therapeutics for prevention and reversal of cardiac pathology associated with heart failure and cardiac enlargement. Over recent years, dramatic progress has been made in unravelling the cellular circuitry involved in cardiac failure, as well as in normal cardiac growth, development and apoptosis. This work has revealed new and unexpected therapeutic targets in the heart. In addition, advances in understanding the role of stem cells in cardiac physiology have suggested strategies for cardiac repair and regeneration once thought impossible. This book describes the work of leading investigators studying the basic mechanisms of cardiac growth, function and dysfunction. There are also exciting contributions from researchers developing novel therapeutic strategies for cardiac disease. The unique feature is the discussions amongst the contributors, which always return to the same basic problem: how can new data from biological studies be used to design novel therapies for the treatment of cardiac dysfunction following myocardial infarction, hypertension and other disorders? With its strong emphasis on translational research, this book will appeal to both scientists and clinicians interested in diminishing the impact of the current epidemic of cardiac diseases.
The Novartis Foundation is an international scientific and educational charity which promotes the study and general knowledge of science and in particular encourages international co-operation in scientific research.
Introduction (Eric N. Olson).
Control of cardiac hypertrophy and heart failure by histone
acetylation/deacetylation (Eric N. Olson, Johannes Backs and
Timothy A. McKinsey) .
Discussion.
A novel mechanism of mechanical stress-induced hypertrophy
(Hiroshi Akazawa, Yunzeng Zou and Issei Komuro) .
Discussion.
Controlling cardiomyocyte survival (N. de Jonge, M. J.
Goumans, Daan Lips, Rutger Hassink, Eva J. Vlug, Roy van der Meel,
Christopher Donald Emmerson, Joppe Nijman, Leon de Windt and Pieter
A. Doevendans) .
Discussion.
Mechanisms of angiotensin II-dependent progression to heart
failure (Mona Nemer, Nassim Dali-Youcef, Hao Wang, Anne Aries
and Pierre Paradis) .
Discussion.
Alterations in myocardial gene expression as a basis for
cardiomyopathies and heart failure (Matthew R. Taylor and
Michael R. Bristow) .
Discussion.
Role of the insulin-like growth factor 1
(IGF1)/phosphoinositide-3-kinase (PI3K) pathway mediating
physiological cardiac hypertrophy (Julie R. McMullen and Seigo
Izumo).
Discussion.
Role of Akt in cardiac growth and metabolism(Anthony J.
Muslin and Brian DeBosch).
Discussion.
Novel therapy for heart failure and exercise-induced ventricular
tachycardia based on 'fixing' the leak in ryanodine
receptors (Andrew R. Marks).
Discussion.
General discussion I.
Phospholamban as a therapeutic modality in heart failure
(Guoxiang Chu and Evangelia G. Kranias).
Discussion.
Sarcomere protein gene mutations and inherited heart disease: a
b-cardiac myosin heavy chain mutation causing endocardial
fibroelastosis and heart failure (Mitsuhiro Kamisago, Joachim P.
Schmitt, Dennis McNamara, Christine Seidman and Jonathan G.
Seidman).
Discussion.
The cardiomyocyte cell cycle (Pascal J. E. Lafontant and
Loren J. Field).
Discussion.
Restoration of cardiac function with progenitor cells (Carmen
Urbich, Lothar Rössig and Stefanie Dimmeler).
Discussion.
Signalling pathways in cardiac regeneration (Maria Paola
Santini, Nadine Winn and Nadia Rosenthal).
Discussion.
Beyond small molecule drugs for heart failure: prospects for
gene therapy (Kenneth R. Chien).
Discussion.
Dual roles of telomerase in cardiac protection and repair
(Michael D. Schneider).
Discussion.
Final general discussion.
Closing remarks: historical perspective (Arnold M.
Katz).
Index of contributors.
Subject index.
"...most up-to-date analysis on ways that science might look to
reduce the harsh impact of heart disease." (Electric Review,
February/March 2007)
"This book offers an update in the basic mechanism of heart
failure from the premier investigators in the field." (Doody's
Health Services)
| Erscheint lt. Verlag | 2.11.2006 |
|---|---|
| Reihe/Serie | Novartis Foundation Symposium |
| Sprache | englisch |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Kardiologie / Angiologie |
| Naturwissenschaften ► Biologie ► Mikrobiologie / Immunologie | |
| Technik | |
| Schlagworte | Biotechnologie • Biotechnologie i. d. Biowissenschaften • Biotechnology • Biowissenschaften • Cardiovascular Disease • Cell & Molecular Biology • Kardiovaskuläre Erkrankungen • Kardiovaskuläre Erkrankungen • Life Sciences • Medical Science • Medizin • Zell- u. Molekularbiologie |
| ISBN-10 | 0-470-02932-3 / 0470029323 |
| ISBN-13 | 978-0-470-02932-9 / 9780470029329 |
| Haben Sie eine Frage zum Produkt? |
PDF (Adobe DRM)Größe: 4,1 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
